Legal & General Group Plc Raises Stock Holdings in Bruker Corporation $BRKR

Legal & General Group Plc boosted its holdings in shares of Bruker Corporation (NASDAQ:BRKR) by 15.0% during the 2nd quarter, Holdings Channel.com reports. The firm owned 222,387 shares of the medical research company’s stock after purchasing an additional 29,054 shares during the quarter. Legal & General Group Plc’s holdings in Bruker were worth $9,162,000 as of its most recent SEC filing.

A number of other institutional investors also recently made changes to their positions in the business. Sculptor Capital LP boosted its stake in shares of Bruker by 51.6% during the 1st quarter. Sculptor Capital LP now owns 2,598,438 shares of the medical research company’s stock valued at $108,459,000 after buying an additional 884,423 shares during the last quarter. Goldman Sachs Group Inc. boosted its stake in Bruker by 107.3% during the 1st quarter. Goldman Sachs Group Inc. now owns 1,465,319 shares of the medical research company’s stock valued at $61,162,000 after acquiring an additional 758,301 shares during the last quarter. AQR Capital Management LLC grew its holdings in Bruker by 65.9% during the 1st quarter. AQR Capital Management LLC now owns 1,476,605 shares of the medical research company’s stock worth $60,688,000 after acquiring an additional 586,516 shares in the last quarter. Vaughan Nelson Investment Management L.P. increased its position in shares of Bruker by 71.2% in the 2nd quarter. Vaughan Nelson Investment Management L.P. now owns 1,293,645 shares of the medical research company’s stock worth $53,298,000 after purchasing an additional 537,845 shares during the last quarter. Finally, Nuveen LLC acquired a new stake in shares of Bruker in the 1st quarter valued at about $20,764,000. 79.52% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Bruker

In other news, Director John A. Ornell sold 6,233 shares of Bruker stock in a transaction that occurred on Thursday, November 6th. The stock was sold at an average price of $39.00, for a total transaction of $243,087.00. Following the sale, the director owned 35,212 shares of the company’s stock, valued at approximately $1,373,268. The trade was a 15.04% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Cynthia M. Friend sold 3,535 shares of the business’s stock in a transaction that occurred on Friday, September 12th. The stock was sold at an average price of $32.25, for a total value of $114,003.75. Following the transaction, the director owned 18,016 shares of the company’s stock, valued at approximately $581,016. This represents a 16.40% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 27.30% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on the company. Citigroup decreased their price target on Bruker from $40.00 to $38.00 and set a “neutral” rating for the company in a research note on Monday, August 4th. Redburn Partners set a $60.00 target price on Bruker in a research report on Thursday, November 20th. Rothschild Redb raised Bruker to a “strong-buy” rating in a research report on Thursday, November 20th. Barclays lifted their price objective on shares of Bruker from $40.00 to $45.00 and gave the stock an “overweight” rating in a report on Tuesday, November 4th. Finally, Weiss Ratings reissued a “sell (d)” rating on shares of Bruker in a report on Tuesday, November 25th. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $50.25.

Bruker Price Performance

Shares of BRKR opened at $47.86 on Tuesday. Bruker Corporation has a 12 month low of $28.53 and a 12 month high of $64.64. The company has a debt-to-equity ratio of 1.31, a current ratio of 1.61 and a quick ratio of 0.70. The stock has a fifty day moving average price of $39.19 and a 200 day moving average price of $37.70. The company has a market cap of $7.27 billion, a P/E ratio of 92.04, a PEG ratio of 5.31 and a beta of 1.26.

Bruker (NASDAQ:BRKR) last posted its earnings results on Monday, November 3rd. The medical research company reported $0.45 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.33 by $0.12. The company had revenue of $860.50 million for the quarter, compared to analysts’ expectations of $847.40 million. Bruker had a return on equity of 17.89% and a net margin of 2.31%.The firm’s quarterly revenue was down .5% compared to the same quarter last year. During the same period last year, the business posted $0.60 earnings per share. Bruker has set its FY 2025 guidance at 1.850-1.90 EPS. On average, research analysts forecast that Bruker Corporation will post 2.69 earnings per share for the current year.

Bruker Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, January 2nd. Shareholders of record on Monday, December 8th will be given a $0.05 dividend. The ex-dividend date is Monday, December 8th. This represents a $0.20 annualized dividend and a yield of 0.4%. Bruker’s dividend payout ratio is -125.00%.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.